| 30th March 2016
Healthcare is undergoing a transformative change, which presents challenges to all players in the sector. Factors of change include evolving expectations and requirements from populations and governments, and newcomers to the field that are changing both supply and demand. Established healthcare players like pharma need to control and shape their emerging roles.
In this respect, pharma needs to be more pro-active if it is to strengthen and enhance its role. Its efforts to date seem quite timid.
Translational research organisations are healthcare players who are adjusting their strategies in anticipation of change, thus turning challenges into opportunities. What if pharma learned how to adapt faster and more effectively from these organisations?
Head of Insight Martine Leroy explores this ‘what if’ scenario, outlining the ways that pharma could learn from translational research organisations and improve their approach to the changing healthcare landscape.
In the UK, the National Health System (NHS) is a major factor of change in that it places engagement and responsibility of the population in their own health and care at the centre of its policy. This is focusing the transformation of the healthcare landscape on cost-effective, positive patient outcomes. Translational research organisations are responding by adjusting their strategies to align with the NHS, to contribute to delivering better patient outcomes, faster.
Traditionally, the role of translational research is to increase the volume of basic scientific discovery that goes into clinical research and hopefully, become real clinical innovation. This is because historically, there is a waste of basic scientific learning that goes into clinical research, because of lack of focus and funding, amongst other factors.
| 21st June 2017
Medical congresses are one of the most important and intensive marketing activities a company can undertake. Here Dolan Desai and Dale Choate give you the practical tools and tips you need to create a leading congress experience.
| 15th June 2017
The 21st Century Cures Act was signed into law last December during the Obama administration. It brings numerous changes to the US drug development landscape, impacting patients, academia, research institutions, and industry. Over the last number of months Blue Latitude have been engaging with US pharma companies to help our clients understand its implications and how it could be leveraged.
| 23rd May 2017
What drives us at BLH is the opportunity to make a real difference – and for our clients, that difference is measured both in customer outcomes and commercial outcomes. In the Executional Excellence edition of Perspective magazine, we explore topics around the ‘executional excellence’ theme – creating work that works.